FIELD: biotechnology.
SUBSTANCE: described is a group of inventions comprising a recombinant infectious herpes virus, a nucleic acid for producing said herpesvirus, nucleic acid for producing mature glycoprotein H (gH) of recombinant infectious herpes virus, a vector for producing recombinant infectious herpes virus, a cell for producing recombinant infectious herpesvirus, method for cell destruction using recombinant infectious herpesvirus and a method for cultivation of recombinant infectious herpesvirus in cells in vitro. In one embodiment, the herpes virus comprises a heterologous polypeptide ligand attached to the N-end of the glycoprotein H (gH), which lacks N-terminal region to amino acid at position 48 according to SEQ ID NO: 1.
EFFECT: invention widens the range for producing recombinant infectious herpes viruses.
15 cl, 9 dwg, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DELIVERY OF THERAPEUTIC POLYPEPTIDES VIA PSEUDOTYPED ONCOLYTIC VIRUSES | 2017 |
|
RU2758007C2 |
| CHIMERIC PROTEIN, A SYNTHETIC DNA WHICH CODES SAID PROTEIN, AN EXPRESSION VECTOR, A SYNTHETIC DNA PRODUCING STRAIN AND A METHOD OF PRODUCING PLASMID DNA | 2016 |
|
RU2736472C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETING HER2 | 2016 |
|
RU2753695C2 |
| HERPES VACCINE | 2019 |
|
RU2731073C1 |
| INTRODUCTION OF CONSTRUCTED T CELLS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CANCER | 2017 |
|
RU2757308C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES AND METHODS OF THEIR USE | 2019 |
|
RU2800779C2 |
| NEW CAPSID PROTEINS OF ADENO-ASSOCIATED VIRUS | 2017 |
|
RU2779318C2 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| HER-2-DIRECTED ANTIGEN-BINDING MOLECULES CONTAINING 4-1BBL | 2019 |
|
RU2815451C2 |
| PSEUDO-FAB BASED MULTISPECIFIC BINDING PROTEINS | 2019 |
|
RU2820254C2 |
